BioSpace News Archive

Crinetics Pharmaceuticals, Inc. announced that on October 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2023 results on Tuesday, November 7, 2023.

GC Biopharma Corp. announced that it has presented the successful adoption of SAP SuccessFactor Work Zone, which is a cloud-based HR solution by SAP, at the SAP Success Connect 2023 held on October 3rd in Las Vegas.

Cerevance today announced participation at the upcoming 3rd Annual Needham Biotech Private Company Forum, taking place virtually from October 17 – 18, 2023.

Aruna Bio, Inc. today announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at the BIO Investor Forum being held October 17-18, 2023, in San Francisco, CA.

Ovid Therapeutics Inc. today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke Congress held October 10-12, 2023, in Toronto, Canada on the possible role of nVNS in the treatment of acute neurological injuries.

Oryzon Genomics, S.A. announced today that the company presented an update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the 36th European College held on October 7-10 in Barcelona, Spain.

I-Mab today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380).

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2023 financial results on Monday, November 6, 2023 after the financial markets close.